Search Results - "Krahn, Murray D."

Refine Results
  1. 1

    Estimation of stage‐specific fibrosis progression rates in chronic hepatitis C virus infection: A meta‐analysis and meta‐regression by Thein, Hla‐Hla, Yi, Qilong, Dore, Gregory J., Krahn, Murray D.

    Published in Hepatology (Baltimore, Md.) (01-08-2008)
    “…Published estimates of liver fibrosis progression in individuals with chronic hepatitis C virus (HCV) infection are heterogeneous. We aimed to estimate…”
    Get full text
    Journal Article
  2. 2

    A province-by-province cost-effectiveness analysis and budget impact analysis of one-time birth cohort screening of hepatitis C virus (HCV) infection in Canada by Wong, William W. L., Haines, Alex, Wong, Josephine, Hamadeh, Abdullah, Krahn, Murray D.

    Published in Scientific reports (18-08-2023)
    “…Managing chronic hepatitis C is challenging, as the majority of those infected are asymptomatic. Therefore, to ensure treatments are administered before the…”
    Get full text
    Journal Article
  3. 3

    Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy : a meta-analysis by THEIN, Hla-Hla, QILONG YI, DORE, Gregory J, KRAHN, Murray D

    Published in AIDS (London) (01-10-2008)
    “…To estimate stage-specific transition probabilities in individuals coinfected with HIV and hepatitis C virus (HCV), to examine the effect of covariates on…”
    Get full text
    Journal Article
  4. 4
  5. 5
  6. 6
  7. 7

    Costs for Childhood and Adolescent Cancer, 90 Days Prediagnosis and 1 Year Postdiagnosis: A Population-Based Study in Ontario, Canada by de Oliveira, Claire, PhD, Bremner, Karen E., BSc, Liu, Ning, MSc, Greenberg, Mark L., MD, Nathan, Paul C., MD, MSc, McBride, Mary L., MSc, Krahn, Murray D., MD, MSc

    Published in Value in health (01-03-2017)
    “…Abstract Background Childhood and adolescent cancers are uncommon, but they have important economic and health impacts on patients, families, and health care…”
    Get full text
    Journal Article
  8. 8

    End-of-Life Care for Lung Cancer Patients in the United States and Ontario by WARREN, Joan L, BARBERA, Lisa, BREMNER, Karen E, YABROFF, K. Robin, HOCH, Jeffrey S, BARRETT, Michael J, LUO, Jin, KRAHN, Murray D

    “…Both the United States and Canada offer government-financed health insurance for the elderly, but few studies have compared care at the end of life for cancer…”
    Get full text
    Journal Article
  9. 9

    Influence of socioeconomic status on survival of hepatocellular carcinoma in the Ontario population; a population-based study, 1990-2009 by Jembere, Nathaniel, Campitelli, Michael A, Sherman, Morris, Feld, Jordan J, Lou, Wendy, Peacock, Stuart, Yoshida, Eric, Krahn, Murray D, Earle, Craig, Thein, Hla-Hla

    Published in PloS one (13-07-2012)
    “…Research has shown that people from higher socioeconomic status (SES) have better hepatocellular carcinoma (HCC) survival outcomes, although no such research…”
    Get full text
    Journal Article
  10. 10

    Benefits and harms of prostate cancer screening - predictions of the ONCOTYROL prostate cancer outcome and policy model by Mühlberger, Nikolai, Boskovic, Kristijan, Krahn, Murray D, Bremner, Karen E, Oberaigner, Willi, Klocker, Helmut, Horninger, Wolfgang, Sroczynski, Gaby, Siebert, Uwe

    Published in BMC public health (26-06-2017)
    “…A recent recalibration of the ONCOTYROL Prostate Cancer Outcome and Policy (PCOP) Model, assuming that latent prostate cancer (PCa) detectable at autopsy might…”
    Get full text
    Journal Article
  11. 11
  12. 12

    Developing the Breast Utility Instrument to Measure Health-Related Quality-of-Life Preferences in Patients with Breast Cancer: Selecting the Item for Each Dimension by Tsui, Teresa C. O., Trudeau, Maureen E., Mitsakakis, Nicholas, Krahn, Murray D., Davis, Aileen M.

    Published in MDM policy & practice (01-07-2022)
    “…Introduction. Generic preference-based instruments inadequately measure breast cancer (BrC) health-related quality-of-life preferences given advances in…”
    Get full text
    Journal Article
  13. 13

    Cost-Utility Analysis of Primary Prophylaxis Versus Secondary Prophylaxis With Granulocyte Colony-Stimulating Factor in Elderly Patients With Diffuse Aggressive Lymphoma Receiving Curative-Intent Chemotherapy by CHAN, Kelvin K. W, SIU, Eric, KRAHN, Murray D, IMRIE, Kevin, ALIBHAI, Shabbir M. H

    Published in Journal of clinical oncology (01-04-2012)
    “…The 2006 American Society of Clinical Oncology (ASCO) guideline recommended primary prophylaxis (PP) with granulocyte colony-stimulating factor (G-CSF) instead…”
    Get full text
    Journal Article
  14. 14

    Do Older Men Benefit From Curative Therapy of Localized Prostate Cancer? by ALIBHAI, Shabbir M. H, NAGLIE, Gary, NAM, Robert, TRACHTENBERG, John, KRAHN, Murray D

    Published in Journal of clinical oncology (01-09-2003)
    “…Prior decision-analytic models are based on outdated or suboptimal efficacy, patient preference, and comorbidity data. We estimated life expectancy (LE) and…”
    Get full text
    Journal Article
  15. 15

    Health-Related Quality of Life Changes Associated With Hearing Loss by Dixon, Peter R, Feeny, David, Tomlinson, George, Cushing, Sharon, Chen, Joseph M, Krahn, Murray D

    Published in JAMA otolaryngology-- head & neck surgery (01-07-2020)
    “…Utility is a single-value, preference-based measure of health-related quality of life that represents the desirability of a health state relative to being dead…”
    Get more information
    Journal Article
  16. 16

    Pharmacotherapy vs surgery as initial therapy for patients with moderate‐to‐severe benign prostate hyperplasia: a cost‐effectiveness analysis by Erman, Aysegul, Masucci, Lisa, Krahn, Murray D., Elterman, Dean S.

    Published in BJU international (01-11-2018)
    “…Objective To evaluate the cost‐effectiveness of using a surgery, such as transurethral resection of the prostate (TURP) or photoselective vaporisation of the…”
    Get full text
    Journal Article
  17. 17

    Using a Health Economic Framework to Prioritize Quality Indicators: An Example With Smoking Cessation in Chronic Obstructive Pulmonary Disease by Nam, Austin, Naimark, David M. J., Stanbrook, Matthew B., Krahn, Murray D.

    Published in MDM policy & practice (2019)
    “…Background. Health care performance monitoring is a major focus of the modern quality movement, resulting in widespread development of quality indicators and…”
    Get full text
    Journal Article
  18. 18

    Does cirrhosis affect quality of life in hepatitis C virus-infected patients? by Hsu, Priscilla C., Krajden, Mel, Yoshida, Eric M., Anderson, Frank H., Tomlinson, George A., Krahn, Murray D.

    Published in Liver international (01-03-2009)
    “…Background: Hepatitis C virus (HCV) infection is a major cause of chronic liver disease and is associated with impairments in health‐related quality of life…”
    Get full text
    Journal Article
  19. 19

    Valuing Health State: An EQ-5D-5L Value Set for Ethiopians by Welie, Abraham G., Gebretekle, Gebremedhin Beedemariam, Stolk, Elly, Mukuria, Clara, Krahn, Murray D., Enquoselassie, Fikre, Fenta, Teferi Gedif

    Published in Value in health regional issues (01-09-2020)
    “…There is a growing interest in health technology assessment and economic evaluations in developing countries such as Ethiopia. The objective of this study was…”
    Get full text
    Journal Article
  20. 20

    Impact of direct‐acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis c: Systematic review and meta‐analysis by Sahakyan, Yeva, Lee‐Kim, Victoria, Bremner, Karen E., Bielecki, Joanna M., Krahn, Murray D.

    Published in Journal of viral hepatitis (01-05-2021)
    “…The long‐term effects of direct‐acting antiviral therapies (DAAs) for chronic hepatitis C (CHC) remain uncertain. The objective of this systematic review and…”
    Get full text
    Journal Article